Abstract
- Kröger J.
- Zietemann V.
- Enzenbach C.
- Weikert C.
- Jansen E.H.
- Doring F.
- Joost H.G.
- Boeing H.
- Schulze M.B.
- Tintle N.L.
- Pottala J.V.
- Lacey S.
- Ramachandran V.
- Westra J.
- Rogers A.
- Clark J.
- Olthoff B.
- Larson M.
- Harris W.
- Wu J.H.
- Lemaitre R.N.
- Manichaikul A.
- Guan W.
- Tanaka T.
- Foy M.
- Kabagambe E.K.
- Djousse L.
- Siscovick D.
- Fretts A.M.
MATERIALS AND METHODS
Study cohorts
FA measurements
Study | Ethnicity | N | Age, Year | Men, % | Sample Type | FAs (%) | |||||
---|---|---|---|---|---|---|---|---|---|---|---|
16:1n-7 | 18:1n-7 | 18:1n-9 | 20:1n-9 | 22:1n-9 | 24:1n-9 | ||||||
Chinese populations | |||||||||||
NHAPC | Chinese | 2,865 | 58.6 (6.0) | 43.2 | RBC | 0.41 (0.20) | 1.02 (0.17) | 11.1(1.38) | 0.29 (0.15) | 0.16 (0.18) | 4.21 (1.78) |
MESA Chinese | Chinese-American | 656 | 62.5 (10.3) | 48.6 | Plasma PL | 0.44 (0.16) | 1.50 (0.25) | 7.30(1.10) | 0.14 (0.05) | NA | 0.80 (0.44) |
European populations | |||||||||||
ARIC | European-American | 3,269 | 53.8 (5.6) | 48.7 | Plasma PL | — | NA | — | 0.12 (0.03) | NI | 0.57 (0.17) |
CARDIA | European-American | 1,507 | 45.8 (3.4) | 46.7 | Plasma PL | — | 1.24 (0.34) | — | 0.12 (0.03) | NA | 0.69 (0.33) |
CHS | European-American | 2,404 | 75.0 (5.1) | 38.4 | Plasma PL | — | 1.30 (0.20) | — | 0.12 (0.03) | 0.03 (0.01) | 1.92 (0.42) |
GOLDN | European-American | 1,123 | 48.2 (16.3) | 48.2 | RBC | — | NA | — | 0.17 (0.13) | NA | NA |
NHS | European-American | 655 | 59.9 (6.5) | 0 | RBC | — | 1.20 (0.21) | — | 0.18 (0.06) | NA | 2.73 (0.71) |
HPFS | European-American | 1,295 | 64.3 (8.6) | 100 | RBC | — | 1.08 (0.14) | — | 0.19 (0.04) | NA | 3.76 (0.79) |
InCHIANTI | European-Italian | 1,075 | 68.4 (15.5) | 45.1 | Plasma | — | 1.37 (0.37) | — | 0.21 (0.06) | 0.78 (0.72) | 0.34 (0.24) |
MESA White | European-American | 692 | 61.6 (10.4) | 47.3 | Plasma PL | — | 1.34 (0.23) | — | 0.13 (0.06) | NA | 0.53 (0.30) |
Genotyping and quality control
Chinese- and European-specific GWAS meta-analyses
Trans-ethnic meta-analysis
cis-Expression quantitative trait loci analysis
FA and Gene | SNP | Chr | Position | EA/NEA | EAF, Chinese/Europeans | Chinese | European | MANTRA | METAL | ||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
β (SE) | P | β (SE) | P | BF | Phet | β (SE) | P | ||||||
Novel associations | |||||||||||||
18:1n-7 | |||||||||||||
PKD2L1/SCD | rs603424 | 10 | 102,065,469 | A/G | 0.072/0.204 | −0.016 (0.009) | 0.065 | −0.035 (0.004) | 5.75 × 10−17 | 14.8 | 0.090 | −0.032 (0.004) | 1.65 × 10−16 |
FADS1/2 | rs174528 | 11 | 61,300,075 | C/T | 0.389/0.368 | 0.013 (0.005) | 3.67 × 10−3 | 0.021 (0.004) | 9.90 × 10−9 | 8.07 | 0.023 | 0.018 (0.003) | 7.22 × 10−10 |
20:1n-9 | |||||||||||||
FADS1/2 | rs174601 | 11 | 61,379,716 | T/C | 0.536/0.365 | 0.008 (0.002) | 1.09 × 10−3 | 0.007 (0.001) | 3.99 × 10−38 | 43.2 | 0.007 | 0.007 (0.001) | 1.47 × 10−45 |
GCKR | rs780094 | 2 | 27,594,741 | T/C | 0.490/0.412 | −0.002 (0.002) | 0.450 | −0.002 (0.000) | 6.31 × 10−7 | 6.22 | 0.007 | −0.002 (0.000) | 2.95 × 10−8 |
Previously reported associations | |||||||||||||
16:1n-7 | |||||||||||||
FADS1/2 | rs102275 | 11 | 61,314,379 | C/T | 0.432/0.329 | 0.021 (0.005) | 1.39 × 10−5 | 0.023 (0.003) | 2.22 × 10−12 | 14.6 | 0.006 | 0.022 (0.003) | 2.49 × 10−16 |
PKD2L1 | rs603424 | 10 | 102,065,469 | A/G | 0.073/0.192 | −0.023 (0.009) | 6.57 × 10−3 | −0.032 (0.004) | 5.32 × 10−14 | 13.0 | 0.016 | −0.030 (0.004) | 4.24 × 10−15 |
GCKR | rs780093 | 2 | 27,596,107 | T/C | 0.524/0.409 | 0.017 (0.005) | 1.36 × 10−4 | 0.020 (0.003) | 3.42 × 10−9 | 10.3 | 0.020 | 0.019 (0.003) | 4.47 × 10−12 |
HIF1AN | rs10883511 | 10 | 102,289,397 | G/A | 0.143/0.213 | 0.026 (0.007) | 1.90 × 10−4 | 0.023 (0.004) | 6.44 × 10−8 | 8.84 | 0.019 | 0.024 (0.004) | 7.90 × 10−11 |
18:1n-9 | |||||||||||||
FADS1/2 | rs102275 | 11 | 61,314,379 | C/T | 0.419/0.329 | 0.204 (0.032) | 2.92 × 10−10 | 0.229 (0.020) | 1.10 × 10−31 | 38.0 | 0.061 | 0.222 (0.017) | 1.44 × 10−39 |
LPCAT3 | rs12579775 | 12 | 6,955,432 | A/G | 0.032/0.094 | −0.539 (0.096) | 1.86 × 10−8 | 0.024 (0.032) | 0.451 | 6.12 | 1 | −0.034 (0.031) | 0.282 |
- Wu J.H.
- Lemaitre R.N.
- Manichaikul A.
- Guan W.
- Tanaka T.
- Foy M.
- Kabagambe E.K.
- Djousse L.
- Siscovick D.
- Fretts A.M.
Gene- and pathway-based analysis
Associations of the identified loci with cardiometabolic outcomes
RESULTS
Cohort characteristics
Novel genetic associations
Previously reported genetic associations
- Wu J.H.
- Lemaitre R.N.
- Manichaikul A.
- Guan W.
- Tanaka T.
- Foy M.
- Kabagambe E.K.
- Djousse L.
- Siscovick D.
- Fretts A.M.
- Tintle N.L.
- Pottala J.V.
- Lacey S.
- Ramachandran V.
- Westra J.
- Rogers A.
- Clark J.
- Olthoff B.
- Larson M.
- Harris W.
- Wu J.H.
- Lemaitre R.N.
- Manichaikul A.
- Guan W.
- Tanaka T.
- Foy M.
- Kabagambe E.K.
- Djousse L.
- Siscovick D.
- Fretts A.M.
- Tintle N.L.
- Pottala J.V.
- Lacey S.
- Ramachandran V.
- Westra J.
- Rogers A.
- Clark J.
- Olthoff B.
- Larson M.
- Harris W.
- Wu J.H.
- Lemaitre R.N.
- Manichaikul A.
- Guan W.
- Tanaka T.
- Foy M.
- Kabagambe E.K.
- Djousse L.
- Siscovick D.
- Fretts A.M.
- Wu J.H.
- Lemaitre R.N.
- Manichaikul A.
- Guan W.
- Tanaka T.
- Foy M.
- Kabagambe E.K.
- Djousse L.
- Siscovick D.
- Fretts A.M.
- Tintle N.L.
- Pottala J.V.
- Lacey S.
- Ramachandran V.
- Westra J.
- Rogers A.
- Clark J.
- Olthoff B.
- Larson M.
- Harris W.
Fine mapping
- Wu J.H.
- Lemaitre R.N.
- Manichaikul A.
- Guan W.
- Tanaka T.
- Foy M.
- Kabagambe E.K.
- Djousse L.
- Siscovick D.
- Fretts A.M.
cis-eQTL analysis
Gene- and pathway-based analysis
- Wu J.H.
- Lemaitre R.N.
- Manichaikul A.
- Guan W.
- Tanaka T.
- Foy M.
- Kabagambe E.K.
- Djousse L.
- Siscovick D.
- Fretts A.M.
Associations of the identified loci with cardiometabolic outcomes
DISCUSSION
- Wu J.H.
- Lemaitre R.N.
- Manichaikul A.
- Guan W.
- Tanaka T.
- Foy M.
- Kabagambe E.K.
- Djousse L.
- Siscovick D.
- Fretts A.M.
- Wu J.H.
- Lemaitre R.N.
- Manichaikul A.
- Guan W.
- Tanaka T.
- Foy M.
- Kabagambe E.K.
- Djousse L.
- Siscovick D.
- Fretts A.M.
Acknowledgments
Supplementary Material
References
- Fatty acids as biocompounds: their role in human metabolism, health and disease–a review. Part 1: classification, dietary sources and biological functions.Biomed. Pap. Med. Fac. Univ. Palacky Olomouc Czech Repub. 2011; 155: 117-130
- Food sources of energy and nutrients among adults in the US: NHANES 2003–2006.Nutrients. 2012; 4: 2097-2120
- Functional roles of fatty acids and their effects on human health.JPEN J. Parenter. Enteral Nutr. 2015; 39: 18S-32S
- Fatty acid metabolism in adipose tissue, muscle and liver in health and disease.Essays Biochem. 2006; 42: 89-103
- Fatty acids as biocompounds: their role in human metabolism, health and disease: a review. Part 2: fatty acid physiological roles and applications in human health and disease.Biomed. Pap. Med. Fac. Univ. Palacky Olomouc Czech Repub. 2011; 155: 195-218
- Monounsaturated fatty acids, olive oil and blood pressure: epidemiological, clinical and experimental evidence.Public Health Nutr. 2006; 9: 251-257
- Role of cis-monounsaturated fatty acids in the prevention of coronary heart disease.Curr. Atheroscler. Rep. 2016; 18: 38
- Current evidence supporting the link between dietary fatty acids and cardiovascular disease.Lipids. 2016; 51: 507-517
- Identification of a lipokine, a lipid hormone linking adipose tissue to systemic metabolism.Cell. 2008; 134: 933-944
- Erythrocyte membrane phospholipid fatty acids, desaturase activity, and dietary fatty acids in relation to risk of type 2 diabetes in the European Prospective Investigation into Cancer and Nutrition (EPIC)-Potsdam Study.Am. J. Clin. Nutr. 2011; 93: 127-142
- Circulating palmitoleic acid and risk of metabolic abnormalities and new-onset diabetes.Am. J. Clin. Nutr. 2010; 92: 1350-1358
- Endogenous red blood cell membrane fatty acids and sudden cardiac arrest.Metabolism. 2010; 59: 1029-1034
- Fatty acids in the de novo lipogenesis pathway and risk of coronary heart disease: the Cardiovascular Health Study.Am. J. Clin. Nutr. 2011; 94: 431-438
- Long-chain monounsaturated fatty acids and incidence of congestive heart failure in 2 prospective cohorts.Circulation. 2013; 127: 1512-1521
- Associations of erythrocyte palmitoleic acid with adipokines, inflammatory markers, and the metabolic syndrome in middle-aged and older Chinese.Am. J. Clin. Nutr. 2012; 96: 970-976
- Associations of erythrocyte fatty acids in the de novo lipogenesis pathway with risk of metabolic syndrome in a cohort study of middle-aged and older Chinese.Am. J. Clin. Nutr. 2013; 98: 319-326
- A genome-wide association study of saturated, mono- and polyunsaturated red blood cell fatty acids in the Framingham Heart Offspring Study.Prostaglandins Leukot. Essent. Fatty Acids. 2015; 94: 65-72
- Genome-wide association study identifies novel loci associated with concentrations of four plasma phospholipid fatty acids in the de novo lipogenesis pathway: results from the Cohorts for Heart and Aging Research in Genomic Epidemiology (CHARGE) consortium.Circ. Cardiovasc Genet. 2013; 6: 171-183
- Diet and gene expression: delta-5 and delta-6 desaturases in healthy Chinese and European subjects.Ann. Nutr. Metab. 2006; 50: 492-498
- Distributions of C-reactive protein and its association with metabolic syndrome in middle-aged and older Chinese people.J. Am. Coll. Cardiol. 2007; 49: 1798-1805
- Multi-ethnic study of atherosclerosis: objectives and design.Am. J. Epidemiol. 2002; 156: 871-881
- The Atherosclerosis Risk in Communities (ARIC) Study: design and objectives. The ARIC investigators.Am. J. Epidemiol. 1989; 129: 687-702
- CARDIA: study design, recruitment, and some characteristics of the examined subjects.J. Clin. Epidemiol. 1988; 41: 1105-1116
- The Cardiovascular Health Study: design and rationale.Ann. Epidemiol. 1991; 1: 263-276
- Association of common C-reactive protein (CRP) gene polymorphisms with baseline plasma CRP levels and fenofibrate response: the GOLDN study.Diabetes Care. 2008; 31: 910-915
- The Nurses' Health Study: 20-year contribution to the understanding of health among women.J. Womens Health. 1997; 6: 49-62
- Prospective study of alcohol consumption and risk of coronary disease in men.Lancet. 1991; 338: 464-468
- Subsystems contributing to the decline in ability to walk: bridging the gap between epidemiology and geriatric practice in the InCHIANTI study.J. Am. Geriatr. Soc. 2000; 48: 1618-1625
- MaCH: using sequence and genotype data to estimate haplotypes and unobserved genotypes.Genet. Epidemiol. 2010; 34: 816-834
- A unified approach to genotype imputation and haplotype-phase inference for large data sets of trios and unrelated individuals.Am. J. Hum. Genet. 2009; 84: 210-223
- Imputation-based analysis of association studies: candidate regions and quantitative traits.PLoS Genet. 2007; 3: e114
- A new multipoint method for genome-wide association studies by imputation of genotypes.Nat. Genet. 2007; 39: 906-913
- Practical aspects of imputation-driven meta-analysis of genome-wide association studies.Hum. Mol. Genet. 2008; 17: R122-R128
- Genomic control for association studies.Biometrics. 1999; 55: 997-1004
- Transethnic meta-analysis of genomewide association studies.Genet. Epidemiol. 2011; 35: 809-822
- HaploReg v4: systematic mining of putative causal variants, cell types, regulators and target genes for human complex traits and disease.Nucleic Acids Res. 2016; 44: D877-D881
- Adaptive gene- and pathway-trait association testing with GWAS summary statistics.Bioinformatics. 2016; 32: 1178-1184
- GATES: a rapid and powerful gene-based association test using extended Simes procedure.Am. J. Hum. Genet. 2011; 88: 283-293
- Comparisons of seven algorithms for pathway analysis using the WTCCC Crohn's Disease dataset.BMC Res. Notes. 2011; 4: 386
- The NIH Roadmap Epigenomics Mapping Consortium.Nat. Biotechnol. 2010; 28: 1045-1048
- Gene-based tests of association.PLoS Genet. 2011; 7: e1002177
- Biochemical and physiological function of stearoyl-CoA desaturase.Am. J. Physiol. Endocrinol. Metab. 2009; 297: E28-E37
- Genetic variants of the FADS1 FADS2 gene cluster as related to essential fatty acid metabolism.Curr. Opin. Lipidol. 2010; 21: 64-69
- Palmitic acid (16:0) competes with omega-6 linoleic and omega-3 alpha-linolenic acids for FADS2 mediated delta 6-desaturation.Biochim. Biophys. Acta. 2016; 1861: 91-97
- Molecular physiology of mammalian glucokinase.Cell. Mol. Life Sci. 2009; 66: 27-42
- Analysis of the co-operative interaction between the allosterically regulated proteins GK and GKRP using tryptophan fluorescence.Biochem. J. 2014; 459: 551-564
- The P446L variant in GCKR associated with fasting plasma glucose and triglyceride levels exerts its effect through increased glucokinase activity in liver.Hum. Mol. Genet. 2009; 18: 4081-4088
- Identification and characterization of a major liver lysophosphatidylcholine acyltransferase.J. Biol. Chem. 2008; 283: 8258-8265
- Fine mapping of type 2 diabetes susceptibility loci.Curr. Diab. Rep. 2014; 14: 549
- Comparing methods for performing trans-ethnic meta-analysis of genome-wide association studies.Hum. Mol. Genet. 2013; 22: 2303-2311
- Genome-wide meta-analyses identify novel loci associated with n-3 and n-6 polyunsaturated fatty acid levels in Chinese and European-ancestry populations.Hum. Mol. Genet. 2016; 25: 1215-1224
Article info
Publication history
Footnotes
Abbreviations
ARICInfrastructure for the CHARGE Consortium was supported in part by the National Heart, Lung, and Blood Institute grant HL105756. The NHAPC study was supported by the major project of the Ministry of Science and Technology of China (2016YFC1304903) and the National Natural Science Foundation of China (81471013, 30930081, 81170734, and 81321062). The ARIC Study was carried out as a collaborative study supported by National Heart, Lung, and Blood Institute contracts HHSN268201100005C, HHSN268201100006C, HHSN268201100007C, HHSN268201100008C, HHSN268201100009C, HHSN268201100010C, HHSN268201100011C, and HHSN268201100012C and grants R01HL087641, R01HL59367, and R01HL086694; National Human Genome Research Institute contract U01HG004402; and National Institutes of Health contract HHSN268200625226C. Infrastructure was partly supported by grant UL1RR025005, a component of the National Institutes of Health and NIH Roadmap for Medical Research. The CARDIA study was conducted and supported by the National Heart, Lung, and Blood Institute in collaboration with the University of Alabama at Birmingham (HHSN268201300025C and HHSN268201300026C), Northwestern University (HHSN268201300027C), University of Minnesota (HHSN268201300028C), Kaiser Foundation Research Institute (HHSN268201300029C), and Johns Hopkins University School of Medicine (HHSN268200900041C). CARDIA is also partially supported by the Intramural Research Program of the National Institute on Aging . Genotyping of the CARDIA participants was supported by National Human Genome Research Institute grants U01-HG-004729, U01-HG-004446, and U01-HG-004424. Statistical analyses and FA measures were funded by National Heart, Lung, and Blood Institute grant R01-HL-084099 (M.F.). The CHS was supported by National Heart, Lung, and Blood Institute contracts HHSN268201200036C, HHSN268200800007C, N01HC55222, N01HC85079, N01HC85080, N01HC85081, N01HC85082, N01HC85083, and N01HC85086; and National Heart, Lung, and Blood Institute grants U01HL080295, R01HL087652, R01HL105756, R01HL103612, R01HL120393, and R01HL085710, with additional contribution from the National Institute of Neurological Disorders and Stroke . Additional support was provided through National Institute on Aging grant R01AG023629. The provision of genotyping data was supported in part by the National Center for Advancing Translational Sciences CTSI grant UL1TR000124 and the National Institute of Diabetes and Digestive and Kidney Diseases Diabetes Research Center grant DK063491 to the Southern California Diabetes Endocrinology Research Center. The HPFS and NHS were supported by National Institutes of Health research grants UM1 CA186107, R01 HL034594, UM1 CA167552, R01 HL35464, HL60712, and CA055075; National Heart, Lung, and Blood Institute career development award R00HL098459; American Diabetes Association research grant 1-12-JF-13; and American Heart Association grant 11SDG7380016. The MESA study and MESA SHARe were supported by National Heart, Lung, and Blood Institute contracts N01-HC-95159 through N01-HC-95169 and RR-024156. Funding for MESA SHARe genotyping was provided by National Heart, Lung, and Blood Institute contract N02HL64278. The provision of genotyping data was supported in part by the National Center for Advancing Translational Sciences CTSI grant UL1TR000124 and the National Institute of Diabetes and Digestive and Kidney Diseases Diabetes Research Center grant DK063491 (Southern California Diabetes Endocrinology Research Center). The GOLDN study was funded by National Heart, Lung, and Blood Institute grants U01HL072524 and HL54776. The InCHIANTI baseline (1998–2000) was supported as a “targeted project” (ICS110.1/RF97.71) by the Italian Ministry of Health and in part by National Institute on Aging contracts 263 MD 9164 and 263 MD 821336. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.
Identification
Copyright
User license
Creative Commons Attribution (CC BY 4.0) |
Permitted
- Read, print & download
- Redistribute or republish the final article
- Text & data mine
- Translate the article
- Reuse portions or extracts from the article in other works
- Sell or re-use for commercial purposes
Elsevier's open access license policy